Back to Journals » International Journal of Nanomedicine » Volume 6

Preliminary biocompatibility investigation of magnetic albumin nanosphere designed as a potential versatile drug delivery system

Authors Estevanato, Cintra, Baldini, Portilho, Barbosa, Martins, Lacava, Miranda-Vilela AL, Tedesco A, Ba¡o, Morais, Lacava Z

Published 18 August 2011 Volume 2011:6 Pages 1709—1717


Review by Single-blind

Peer reviewer comments 3

Luciana Estevanato1, Débora Cintra1, Nayara Baldini1, Flávia Portilho1, Luzirlane Barbosa1, Olímpia Martins2, Bruno Lacava3, Ana Luisa Miranda-Vilela1, Antônio Cláudio Tedesco2, Sônia Báo1, Paulo C Morais4, Zulmira GM Lacava1
1Instituto de Ciências Biológicas, Universidade de Brasília, 2Departamento de Química, Laboratório de Fotobiologia e Fotomedicina, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 3Instituto de Química, Universidade de Brasília, Brasília, 4Instituto de Física, Universidade de Brasília, Brasília, Brazil

Background: The magnetic albumin nanosphere (MAN), encapsulating maghemite nanoparticles, was designed as a magnetic drug delivery system (MDDS) able to perform a variety of biomedical applications. It is noteworthy that MAN was efficient in treating Ehrlich's tumors by the magnetohyperthermia procedure.
Methods and materials: In this study, several nanotoxicity tests were systematically carried out in mice from 30 minutes until 30 days after MAN injection to investigate their biocompatibility status. Cytometry analysis, viability tests, micronucleus assay, and histological analysis were performed.
Results: Cytometry analysis and viability tests revealed MAN promotes only slight and temporary alterations in the frequency of both leukocyte populations and viable peritoneal cells, respectively. Micronucleus assay showed absolutely no genotoxicity or cytotoxicity effects and histological analysis showed no alterations or even nanoparticle clusters in several investigated organs but, interestingly, revealed the presence of MAN clusters in the central nervous system (CNS).
Conclusion: The results showed that MAN has desirable in vivo biocompatibility, presenting potential for use as a MDDS, especially in CNS disease therapy.

Keywords: nanotoxicity, nanoparticle, genotoxicity, cytotoxicity, brain

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Quantitative approach to skin field cancerization using a nanoencapsulated photodynamic therapy agent: a pilot study

Passos SK, de Souza PE, Soares PK, Eid DR, Primo FL, Tedesco AC, Lacava ZG, Morais PC

Clinical, Cosmetic and Investigational Dermatology 2013, 6:51-59

Published Date: 20 February 2013

Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacy

Estevanato LC, Da Silva JR, Falqueiro AM, Mosiniewicz-Szablewska E, Suchocki P, Tedesco AC, Morais PC, Lacava ZG

International Journal of Nanomedicine 2012, 7:5287-5299

Published Date: 5 October 2012

Anti-CEA loaded maghemite nanoparticles as a theragnostic device for colorectal cancer

Campos da Paz M, Almeida Santos MF, Santos CM, da Silva SW, de Souza LB, Lima EC, Silva RC, Lucci CM, Morais PC, Azevedo RB, Lacava ZG

International Journal of Nanomedicine 2012, 7:5271-5282

Published Date: 4 October 2012

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010